Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00801333|
Recruitment Status : Recruiting
First Posted : December 3, 2008
Last Update Posted : August 8, 2019
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.
The major goal of the project is to develop human iPS cells from various types of cell cultures or lines from existing collections. The IPS cells will be developed for modeling diseases, for developing the technology that may eventually allow the use of IPS cells for transplantation therapy, and for basic research.
|Condition or disease|
|Amyotrophic Lateral Sclerosis|
The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.
We will induce the differentiation of the iPS cells towards specific cell lineages and the progeny can be used to study the pathogenesis of diseases. They will be used for developing new therapeutic approaches and for high throughput screening of factors for potential toxic or therapeutic effects.
All samples will be non-identified.
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Official Title:||Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells|
|Actual Study Start Date :||November 2008|
|Estimated Primary Completion Date :||December 2025|
|Estimated Study Completion Date :||December 2025|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801333
|Contact: Benjamin E. Reubinoff, M.D. PhD.||firstname.lastname@example.org|
|Contact: Shelly E Tannenbaum, MSQAemail@example.com|
|Hadassah Medical Organization - Ein Kerem Campus||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Hadas Lemberg, PhD 011-972-2-677-6095 Lhadas@hadassah.org.il|